Chlamydia Pneumonia Infection and Incidence of Age-Related Macular Degeneration
Principal Investigator
Luba Robman, MBBS, PhD
Centre for Eye Research Australia (Australia)
Melbourne, Australia
About the Research Project
Program
Award Type
Standard
Award Amount
$50,000
Active Dates
April 01, 2005 - March 31, 2006
Grant ID
M2005012
Summary
Recent studies have indicated an inflammatory component in the development of age-related macular degeneration (AMD). It is biologically plausible that such an inflammation is either caused by or aggravated in the presence of chronic infection. Two cross-sectional studies have demonstrated the prevalence of antibodies to Chlamydia pneumonia elementary bodies to be significantly higher in subjects with AMD compared to age-matched controls. Dr. Robman believes that Chlamydia pneumonia infection may play a causal role in the development of AMD and, therefore, aims to test an association between exposure to the Chlamydia pneumonia infection and the incidence of early AMD. If the causative link between Chlamydia pneumonia infection and the development of AMD is confirmed, long-term clinical trials of antibiotic therapy will be necessary to confirm or refute a pathogenic role for these organisms.
Related Grants
Macular Degeneration Research
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine
Development of an Oral Treatment for Dry AMD Using Everyday Anti-Inflammatory Drugs
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Marco Bassetto, PhD
Current Organization
University of California, Irvine
Macular Degeneration Research
Developing a New Treatment for Wet AMD: Targeted Removal of a Disease-Causing Protein
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Celia Bisbach, PhD
Current Organization
University of Wisconsin-Madison
Developing a New Treatment for Wet AMD: Targeted Removal of a Disease-Causing Protein
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Celia Bisbach, PhD
Current Organization
University of Wisconsin-Madison
Macular Degeneration Research
Sterically Hindered Phenol, PMC, as a Potential Novel Therapeutic for Geographic Atrophy
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Suman Chaudhary, PhD
Current Organization
Schepens Eye Research Institute of Mass. Eye and Ear
Sterically Hindered Phenol, PMC, as a Potential Novel Therapeutic for Geographic Atrophy
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Suman Chaudhary, PhD
Current Organization
Schepens Eye Research Institute of Mass. Eye and Ear